{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:34Z","timestamp":1791568834659,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11102-024-01490-0","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:31:59Z","timestamp":1735173119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland"],"prefix":"10.1007","volume":"28","author":[{"given":"Carlos","family":"Alcaide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"issue":"1\u20132","key":"1490_CR1","first-page":"7","volume":"28","author":"JP Martinez-Barbera","year":"2015","unstructured":"Martinez-Barbera JP, Buslei R (2015) Adamantinomatous craniopharyngioma: Pathology, molecular genetics and mouse models. J Pediatr Endocrinol Metab 28(1\u20132):7\u201317","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1490_CR2","doi-asserted-by":"crossref","unstructured":"M\u00fcller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S, Craniopharyngioma (2019) Nat Rev Dis Prim. 5(1)","DOI":"10.1038\/s41572-019-0125-9"},{"issue":"5","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrendo.2016.217","volume":"13","author":"HL M\u00fcller","year":"2017","unstructured":"M\u00fcller HL, Merchant TE, Puget S, Martinez-Barbera JP (2017) New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 13(5):299\u2013312. https:\/\/doi.org\/10.1038\/nrendo.2016.217","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/er.2006-0002","volume":"27","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Cudlip S, Adams CBT, Wass JAH (2006) Craniopharyngiomas Endocr Rev 27(4):371\u2013397","journal-title":"Craniopharyngiomas Endocr Rev"},{"issue":"5","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s11102-019-00983-7","volume":"22","author":"S Boekhoff","year":"2019","unstructured":"Boekhoff S, Bison B, Eveslage M, Sowithayasakul P, M\u00fcller HL (2019) Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007. Pituitary 22(5):532\u2013541. https:\/\/doi.org\/10.1007\/s11102-019-00983-7","journal-title":"Pituitary"},{"issue":"4","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3171\/2018.6.JNS18901","volume":"131","author":"EG Ord\u00f3\u00f1ez-Rubiano","year":"2019","unstructured":"Ord\u00f3\u00f1ez-Rubiano EG, Forbes JA, Morgenstern PF, Arko L, Dobri GA, Greenfield JP et al (2019) Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas. J Neurosurg 131(4):1163\u20131171","journal-title":"J Neurosurg"},{"issue":"1","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11102-012-0418-4","volume":"16","author":"SJ Larkin","year":"2013","unstructured":"Larkin SJ, Ansorge O (2013) Pathology and pathogenesis of craniopharyngiomas. Pituitary 16(1):9\u201317","journal-title":"Pituitary"},{"issue":"6","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-005-1004-x","volume":"109","author":"R Buslei","year":"2005","unstructured":"Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnr\u00fcbl F et al (2005) Common mutations of \u03b2-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109(6):589\u2013597","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-010-0642-9","volume":"119","author":"A H\u00f6lsken","year":"2010","unstructured":"H\u00f6lsken A, Buchfelder M, Fahlbusch R, Bl\u00fcmcke I, Buslei R (2010) Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated wnt-signalling. Acta Neuropathol 119(5):631\u2013639","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1490_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/stem.2267","volume":"34","author":"JP Martinez-Barbera","year":"2016","unstructured":"Martinez-Barbera JP, Andoniadou CL (2016) Concise Review: Paracrine Role of Stem cells in Pituitary tumors: a focus on Adamantinomatous Craniopharyngioma. Stem Cells 34(2):268\u2013276","journal-title":"Stem Cells"},{"issue":"2","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00401-012-0957-9","volume":"124","author":"CL Andoniadou","year":"2012","unstructured":"Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Le Tissier P et al (2012) Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 124(2):259\u2013271","journal-title":"Acta Neuropathol"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","volume":"21","author":"JL Kirkland","year":"2017","unstructured":"Kirkland JL, Tchkonia T, Cellular Senescence A, Translational Perspective (2017) EBioMedicine 21:21\u201328. https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.013","journal-title":"EBioMedicine"},{"issue":"3","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23723556.2018.1435180","volume":"5","author":"JM Gonzalez-Meljem","year":"2018","unstructured":"Gonzalez-Meljem JM, Martinez-Barbera JP (2018) Senescence drives non-cell autonomous tumorigenesis in the pituitary gland. Mol Cell Oncol 5(3):1\u20133. https:\/\/doi.org\/10.1080\/23723556.2018.1435180","journal-title":"Mol Cell Oncol"},{"issue":"7","key":"1490_CR14","first-page":"881","volume":"29","author":"R Cove\u00f1as","year":"2014","unstructured":"Cove\u00f1as R, Mu\u00f1oz M (2014) Cancer progression and substance P. Histol Histopathol 29(7):881\u2013890","journal-title":"Histol Histopathol"},{"key":"1490_CR15","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz MF, Arg\u00fcelles S, Rosso M, Medina R, Cove\u00f1as R, Ayala A et al (2022) The neurokinin-1 receptor is essential for the viability of human glioma cells: a possible target for treating glioblastoma. Biomed Res Int 2022:6291504. https:\/\/doi.org\/10.1155\/2022\/6291504","DOI":"10.1155\/2022\/6291504"},{"issue":"1","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10555-006-8161-9","volume":"25","author":"F Esteban","year":"2006","unstructured":"Esteban F, Mu\u00f1oz M, Gonz\u00e1lez-Moles MA, Rosso M (2006) A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25(1):137\u2013145","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1210\/jcem-71-5-1089","volume":"71","author":"KA Roth","year":"1990","unstructured":"Roth KA, Krause JE (1990) Substance-P is Present in a subset of Thyrotrophs in the human Pituitary*. J Clin Endocrinol Metab 71(5):1089\u20131095","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12038-015-9530-8","volume":"40","author":"M Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz M, Cove\u00f1as R, Esteban F, Redondo M (2015) The substance P\/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci 40(2):441\u2013463","journal-title":"J Biosci"},{"issue":"19","key":"1490_CR19","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.3390\/jcm12196409","volume":"12","author":"I Isorna","year":"2023","unstructured":"Isorna I, Gonz\u00e1lez-Moles M\u00c1, Mu\u00f1oz M, Esteban F (2023) Substance P and Neurokinin-1 receptor system in thyroid Cancer: potential targets for New Molecular therapies. J Clin Med 12(19):6409","journal-title":"J Clin Med"},{"issue":"5","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE et al (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol 135(5):757\u2013777. https:\/\/doi.org\/10.1007\/s00401-018-1830-2","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1490_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01992-5","volume":"8","author":"J Mario Gonzalez-Meljem","year":"2017","unstructured":"Mario Gonzalez-Meljem J, Haston S, Carreno G, Apps JR, Pozzi S, Stache C et al (2017) Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat Commun 8(1):1\u201314. https:\/\/doi.org\/10.1038\/s41467-017-01992-5","journal-title":"Nat Commun"},{"issue":"2","key":"1490_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4081\/ejh.2020.3117","volume":"64","author":"I Isorna","year":"2020","unstructured":"Isorna I, Esteban F, Solanellas J, Cove\u00f1as R, Mu\u00f1oz M (2020) The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. Eur J Histochem 64(2):139\u2013147","journal-title":"Eur J Histochem"},{"issue":"11","key":"1490_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1210\/jcem-71-5-1089","volume":"20","author":"M Mondal","year":"2014","unstructured":"Mondal M, Mukherjee S, Bhattacharyya D (2014) Contribution of phenylalanine side chain intercalation to the TATA-box binding protein\u2013DNA interaction: molecular dynamics and dispersion-corrected density functional theory studies. J Mol Model 20(11):2499. https:\/\/doi.org\/10.1210\/jcem-71-5-1089","journal-title":"J Mol Model"},{"issue":"9","key":"1490_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092682","volume":"12","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M, Cove\u00f1as R (2020) The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers (Basel) 12(9):1\u201322","journal-title":"Cancers (Basel)"},{"issue":"29","key":"1490_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/newbio232086a0","volume":"232","author":"MM Chang","year":"1971","unstructured":"Chang MM, Leeman SE, Niall HD (1971) Amino-acid sequence of Substance P. Nat New Biol 232(29):86\u201387","journal-title":"Nat New Biol"},{"issue":"21","key":"1490_CR26","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1074\/jbc.M116.770420","volume":"292","author":"Y-X Zhang","year":"2017","unstructured":"Zhang Y-X, Li X-F, Yuan G-Q, Hu H, Song X-Y, Li J-Y et al (2017) \u03b2-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2\/M phase transition. J Biol Chem 292(21):8933\u20138947","journal-title":"J Biol Chem"},{"issue":"2","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","volume":"28","author":"M Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28(2):187\u2013193","journal-title":"Invest New Drugs"},{"issue":"11","key":"1490_CR28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/cbin.10158","volume":"37","author":"G Mei","year":"2013","unstructured":"Mei G, Xia L, Zhou J, Zhang Y, Tuo Y, Fu S et al (2013) Neuropeptide SP activates the WNT signal transduction pathway and enhances the proliferation of bone marrow stromal stem cells. Cell Biol Int 37(11):1225\u20131232. https:\/\/doi.org\/10.1002\/cbin.10158","journal-title":"Cell Biol Int"},{"issue":"12","key":"1490_CR29","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1158\/1535-7163.MCT-15-0206","volume":"14","author":"M Ilmer","year":"2015","unstructured":"Ilmer M, Garnier A, Vykoukal J, Alt E, von Schweinitz D, Kappler R et al (2015) Targeting the Neurokinin-1 receptor compromises canonical wnt signaling in Hepatoblastoma. Mol Cancer Ther 14(12):2712\u20132721","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1490_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3892\/ijo.2015.3016","volume":"47","author":"A Garnier","year":"2015","unstructured":"Garnier A, Vykoukal J, Hubertus J, Alt E, Von Schweinitz D, Kappler R et al (2015) Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol 47(1):151\u2013160","journal-title":"Int J Oncol"},{"issue":"1","key":"1490_CR31","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.1038\/s41598-017-09639-7","volume":"7","author":"JE Lim","year":"2017","unstructured":"Lim JE, Chung E, Son Y (2017) A neuropeptide, Substance-P, directly induces tissue-repairing M2 like macrophages by activating the PI3K\/Akt\/mTOR pathway even in the presence of IFN\u03b3. Sci Rep 7(1):9417","journal-title":"Sci Rep"},{"issue":"13","key":"1490_CR32","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/jcm11133609","volume":"11","author":"P Robinson","year":"2022","unstructured":"Robinson P, Rodriguez E, Mu\u00f1oz M (2022) Substance P-Friend or foe. J Clin Med 11(13):3609. https:\/\/doi.org\/10.3390\/jcm11133609","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"1490_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0165-5728(02)00277-1","volume":"131","author":"C-J Guo","year":"2002","unstructured":"Guo C-J, Lai J-P, Luo H-M, Douglas SD, Ho W-Z (2002) Substance P up-regulates macrophage inflammatory protein-1\u03b2 expression in human T lymphocytes. J Neuroimmunol 131(1\u20132):160\u2013167","journal-title":"J Neuroimmunol"},{"issue":"2","key":"1490_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jcp.20061","volume":"201","author":"TM O\u2019Connor","year":"2004","unstructured":"O\u2019Connor TM, O\u2019Connell J, O\u2019Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201(2):167\u2013180","journal-title":"J Cell Physiol"},{"issue":"Aug","key":"1490_CR35","first-page":"1","volume":"9","author":"S Grob","year":"2019","unstructured":"Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM et al (2019) Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma. Front Oncol 9(Aug):1\u20136","journal-title":"Front Oncol"},{"key":"1490_CR36","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhou W, Xu X, Ge X, Wang F, Zhang G-Q et al (2022) Aprepitant inhibits JNK and p38\/MAPK to attenuate inflammation and suppresses Inflammatory Pain. Front Pharmacol. 12","DOI":"10.3389\/fphar.2021.811584"},{"issue":"6","key":"1490_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N (2019) VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176(6):1248\u20131264","journal-title":"Cell"},{"issue":"5","key":"1490_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"key":"1490_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde PS, Wallin JJ, Mancao C (2018) Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 52:117\u2013124","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"1490_CR40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","volume":"111","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Brekken RA (2022) Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol 111(6):1269\u20131286","journal-title":"J Leukoc Biol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01490-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01490-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01490-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T09:32:58Z","timestamp":1741426378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01490-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01490-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5447351\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"17 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Medical Research Ethics Committee of Hospitales Universitarios Virgen Macarena-Virgen Del Roc\u00edo. Committee that has weighted and evaluated in session held on 26thApril 2018 and collected in minutes 05\/2018.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}